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Salmonella enterica serovar Typhi (S. Typhi) causes
typhoid fever, a life-threatening human disease. The
lack of animal models due to S. Typhi’s strict human
host specificity has hindered its study and vaccine
development. We find that immunodeficient Rag2/
gc/ mice engrafted with human fetal liver hemato-
poietic stem and progenitor cells are able to sup-
port S. Typhi replication and persistent infection.
A S. Typhi mutant in a gene required for virulence in
humans was unable to replicate in these mice.
Another mutant unable to produce typhoid toxin
exhibited increased replication, suggesting a role
for this toxin in the establishment of persistent infec-
tion. Furthermore, infected animals mounted human
innate and adaptive immune responses to S. Typhi,
resulting in the production of cytokines and path-
ogen-specific antibodies. We expect that this mouse
model will be a useful resource for understanding
S. Typhi pathogenesis and for evaluating potential
vaccine candidates against typhoid fever.
INTRODUCTION
Typhoid fever remains a global health problem, resulting in more
than 200,000 annual deaths, mostly of children in developing
countries (Pang et al., 1998; Crump and Mintz, 2010). Unlike
other Salmonella enterica serovars such as S. Typhimurium or
S. Enteritidis, which are associated with gastroenteritis (i.e.,
‘‘food poisoning’’) and can infect a variety of hosts, S. Typhi is
an exclusive human pathogen (Parry et al., 2002). Furthermore,
S. Typhi can cause lifelong infections in humans, most often by
colonizing the gall bladder. The molecular bases for its host
adaptation and ability to cause persistent infection are not
known. However, it is believed that a combination of genome
degradation and acquisition of new genetic information has
conferred on S. Typhi its unique pathogenic properties (Sabbagh
et al., 2010). Although much is known about the pathogenicCell Hosmechanisms of S. enterica in general and some serovars in
particular, remarkably little is known about the unique patho-
genic features of S. Typhi. There are currently no effective
vaccines against typhoid fever and no vaccines that can
be used in young children. The isolation of multidrug-resistant
S. Typhi has raised the worrisome possibility of the reemergence
of untreatable typhoid fever (Mirza et al., 1996). Since S. Typhi is
restricted to humans, there is no suitable animal model (other
than higher primates) in which to study S. Typhi pathogenesis
and test potential vaccines. To study typhoid fever pathogen-
esis, investigators have made use of S. Typhimurium, which in
mice carrying a mutation in nramp1 produces a disease that
resembles typhoid fever (O’Brien et al., 1980). Furthermore,
S. Typhimurium infection of nramp1+/+ mice, which are resistant
to infection, has been used as a model of persistent infection
(Monack et al., 2004). Although these models have been useful
to the understanding of systemic infections by S. enterica in
general, they have been of limited value to the study of patho-
genic mechanisms specific to S. Typhi. Since S. Typhi is in
essence a pathogen of the reticuloendothelial system (Parry
et al., 2002; House et al., 2001) it is possible that determinants
of host specificity and restriction may reside within the reticulo-
endothelial system, since this is the most variable compartment
across different animal species (Flajnik andKasahara, 2010; Bar-
reiro and Quintana-Murci, 2010). Therefore, we sought to inves-
tigate the ability of a mouse with a humanized immune system to
support infection by S. Typhi. We found that immunodeficient
Rag2/ gc/mice engrafted with human fetal liver hematopoi-
etic stem and progenitor cells support S. Typhi replication
and persistent infection. Infected animals mounted a human
innate and adaptive immune response to S. Typhi, resulting in
the production of cytokines and pathogen-specific antibodies.
These results, therefore, indicate that this animal model can be
used to study S. Typhi pathogenesis and to evaluate potential
vaccine candidates against typhoid fever.RESULTS AND DISCUSSION
Immunodeficient mice engrafted with human hematopoietic
stem and progenitor cells have been used to study human
diseases, including immune responses to microbial pathogenst & Microbe 8, 369–376, October 21, 2010 ª2010 Elsevier Inc. 369
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fore engrafted fetal liver CD34+ human hematopoietic stem cells
into the livers of Rag2/ gc/ mice. Previous studies have
shown that these animals support reconstitution of a functional
human immune system (Baenziger et al., 2006; Kuruvilla et al.,
2007; Kwant-Mitchell et al., 2009; Yu et al., 2008). As controls,
we used conditioned newborn Rag2/ gc/ mice injected
with PBS only (Figures 1A and 1B). Average engraftment with
human CD45+ hematopoietic cells was 21.3% (range: 3.7%–
55.4%) in the animals used in this study (Figure 1C). Engrafted
mice developed human lymphocytes (Figures 1D and 1E) as
well as human myeloid cells (Figures 1F and 1G).
We infected groups of engrafted and control animals with an
intraperitoneal dose of wild-type S. Typhi, which in pilot experi-
ments conducted in nonengrafted animals did not result in signif-
icant numbers of bacteria recovered from systemic tissues
4 weeks after infection. Neither the control nor the engrafted
animals showed any symptoms as a consequence of the infec-
tion. However, large numbers of S. Typhi colony-forming units
(cfu) were recovered from liver and spleen of engrafted animals
at 4 weeks after infection (Figures 2A and 2B). In contrast, in
control animals, bacteria were recovered inmuch lower numbers
(Figures 2A and 2B). Furthermore, the engrafted group had
a higher proportion of animals with larger number of S. Typhi
cfu in the gall bladder when compared to the nonengrafted
controls, although this difference did not reach statistical signif-
icance (Figure 2C). This observation may be of interest since the
gall bladder is the preferred site of S. Typhi residency in persis-
tently infected humans (Sinnott and Teall, 1987). We observed
mouse-to-mouse variation in the levels of S. Typhi cfu in human-
ized mice not only between different experiments but also within
a given experiment. We hypothesize that this difference may
have been due to different levels of engraftment, differences in
the lineages of the human cell populations generated in the en-
grafted animals, differences in the genetic makeup of the human
cell donors, or a combination of all these factors. Similar obser-
vations have been made in previous studies using humanized
mice (Brehm et al., 2010).
The mouse Nramp1 protein is known to be very important for
resistance to S. Typhimurium infection in mice, and nramp1/
mice are up to1000-foldmore susceptible to bacterial infection
(Skamene et al., 1998). However, we observed no significant
differences between the levels ofS. Typhi cfu recovered from en-
grafted Rag2/ gc/ nramp1/ or Rag2/ gc/ nramp1+/+
mice (Figure S1). These results indicate that the Nramp1 status
of the mice, which was variable due to the mixed BALB/c 3
129 genetic background, does not influence the outcome of
S. Typhi infection of humanized mice, and they are consistent
with a previous observation indicating that Nramp1 is not
involved in the restriction of S. Typhi replication in mice (O’Brien,
1982). Although these results are consistent with extensive
epidemiological data that have found no association between
nramp1 alleles and typhoid fever susceptibility in humans (Dun-
stan et al., 2001), it is also possible that mouse cells may not
contribute to S. Typhi replication, and hence only the genetic
makeup of the engrafted human cells may be relevant for bacte-
rial replication. Indeed, human CD45+ splenocytes containing
large numbers of S. Typhi were detected in the spleens of
infected animals, indicating that human cells are capable of sup-370 Cell Host & Microbe 8, 369–376, October 21, 2010 ª2010 Elsevieporting bacterial replication (Figure 2D). In contrast, we did not
observe S. Typhi within mouse CD45+ cells (data not shown).
We occasionally observed isolated bacteria in areas of the
spleen not stained by either antibody, which may represent
extracellular bacteria or nondividing bacteria contained within
mouse CD45 cells. We also observed a specific depletion of
human CD45+ cells 4 weeks after infection in the spleens of
infected animals (Figures 2E–2I), suggesting that bacterial repli-
cation may lead to cell death. In contrast, we observed no deple-
tion of mouse CD45+ cells (Figure 2J). Taken together, these
results suggest that human cells may provide a replicative niche
for S. Typhi, although we cannot rule out that human cells only
indirectly contribute to bacterial replication.
Innate and adaptive immune responses are essential to
control S. Typhi infection (Raffatellu et al., 2008; Sztein, 2007).
Therefore, we tested whether S. Typhi infection resulted in
a human innate immune response in the engrafted animals by
measuring the levels of several human cytokines in peripheral
blood 1 and 4 weeks after infection. Only a few infected animals
showed levels of human cytokines above those of control unin-
fected animals 1 week after infection (Figure 3A). In contrast,
4 weeks after infection, a large proportion of the infected animals
showed increased levels of the human cytokines TNFa, IL-8,
IL-10, IL-12, IFNg, MIP-1a, and IP-10 (Figure 3A). These results
indicate that engrafted animals were able to mount a human
innate immune response to S. Typhi. We also tested whether
S. Typhi infection could elicit an acquired human immune
response by measuring the levels of S. Typhi-specific antibody
responses in the sera of engrafted animals 4 weeks after
infection. Significant levels of human antibodies to S. Typhi
were detected in 25% of infected animals but not in the unin-
fected controls (Figure 3B). These results indicate that this model
could be useful for preclinical testing of S. Typhi vaccine
candidates.
A useful animal model should be able to resolve differences
between strains of different virulence. Only a limited number of
S. Typhi mutant strains have been tested in humans for their
virulence properties (Galen et al., 2009). One of them is the
S. Typhi DphoP DphoQ mutant, which has been shown to be
avirulent in human volunteer trials and is being considered as
a potential vaccine candidate (Hohmann et al., 1996). PhoP/
PhoQ is a two-component regulatory system that controls the
expression of several genes that are critical for virulence (Kato
and Groisman, 2008). We therefore compared the levels of cfu
recovered from tissues of engrafted animals infected with either
wild-type or an isogeneic DphoP DphoQ mutant 4 weeks after
infection. We found that the levels of wild-type S. Typhi were
significantly higher than those of the DphoP DphoQ mutant,
and contrary to wild-type, the mutant strain was either not
detected in tissues or was recovered in much lower numbers
(Figures 4A and 4B). Consistent with its poor replication, the
DphoP DphoQ mutant did not stimulate a human immune
response in the engrafted animals (Figure 3B). Typhoid toxin is
a recently identified potential virulence factor of S. Typhi (Hagh-
joo and Gala´n, 2004; Spano` et al., 2008). Exclusively produced
by S. Typhi and S. Paratyphi, this toxin is composed of one
‘‘B’’ subunit, known as PltB, and two active subunits, known
as CdtB and PltA, which have nuclease and the ADP-ribosyl
transferase activities. Although it is known that this toxin isr Inc.
Figure 1. Reconstitution of a Human Immune System in Immunodeficient Mice
(A) Diagram depicting the generation of mice with a human hemato-lymphoid system.
(B) Representative flow cytometric analysis of blood cells from mice injected with PBS or with human CD34+ cells. Numbers next to boxed areas indicate the
percentages of human hematopoietic (hCD45+) cells.
(C) Frequency of human hematopoietic (hCD45+) cells in blood in mice engrafted with human CD34+ cells (n = 125) determined by flow cytometry. Horizontal bar
indicates mean frequency.
(D–G) Flow cytometric analysis of human immune cell populations in engrafted mice. Representative examples of human T (hCD3+) and B cells (hCD19+) in blood
(D) and spleens (E) are shown. Human myeloid (hCD33+ Side Scatterhi), granulocyte (hCD66+ Side Scatterhi), monocyte (hCD14hi), and dendritic cells (hCD11chi
HLA-DRhi) in bonemarrow (F) and blood (G) are also shown. All plots are gated on hCD45+mCD45 cells. Numbers next to boxed/circled areas indicate percent-
ages of cells. Mice were analyzed 8–14 weeks after engraftment.
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Figure 2. Humanized Mice Can Support S. Typhi Replication
(A–C) Colony-forming units recovered from S. Typhi-infected control (left) and humanized (right) mouse spleen (A), liver (B), and gall bladder (C). Control and
humanized mice were infected intraperitoneally with 104 S. Typhi, and cfu of the organs of the infected animals were examined 4 weeks after infection. Data
in (A) and (B) represent three pooled independent experiments (p < 0.0001 for the difference between the number of cfu recovered from humanized and control
animals). Data in (C) represent two pooled independent experiments (n = 19 for control and n = 25 for humanized mice) in which 5 control mice and 10 humanized
mice showed S. Typhi colonization in the gall bladder. Each symbol represents the actual number of cfu per organ of a single mouse. The mean ±SEM are shown.
(D) Immunofluorescence staining of intracellular S. Typhi in humanized mouse spleen. S. Typhi, red; human CD45+ cells, green (scale bar = 10 mm).
(E–J) Flow cytometric analysis of blood cells from mice before (E and F) and splenocytes 4 weeks after (G–J) infection with 104 S. Typhi. Control mice were left
uninfected. Cells were stained with antibodies specific for mouse or human CD45+. The frequency (F–H) and absolute number (I) of human hematopoietic
(hCD45+) cells and the absolute number of mouse hematopoietic (mCD45+) cells (J) are shown. The p values of the difference between frequency/number of
the indicated cells in infected and uninfected animals are 0.722 (F), 0.004 (H), 0.011 (I), and 0.896 (J).
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and Gala´n, 2004), the role of typhoid toxin in S. Typhi pathogen-
esis and infection is unknown. We therefore tested the virulence
of a S. Typhi DpltB mutant strain. PltB is essential for toxin
delivery, so a strain lacking this subunit is unable to intoxicate
cultured epithelial cells (Spano` et al., 2008). Surprisingly, we
found that this mutant strain exhibited increased ability to repli-
cate in the humanized mouse model. Significantly higher cfu of
this mutant were detected in the liver and spleen of humanized
mice. These results suggest the possibility that typhoid toxin
may contribute to the establishment of persistent infection,
perhaps by slowing down S. Typhi replication in infected tissues.372 Cell Host & Microbe 8, 369–376, October 21, 2010 ª2010 ElsevieAdditional studies will be required to understand the role of
typhoid toxin in S. Typhi infection. Taken together, these results
indicate that this model can be used to evaluate the in vivo repli-
cation of S. Typhi mutant strains and could therefore be useful
in the preclinical evaluation of virulence-attenuated vaccine
candidates.
We have shown here that an immunodeficient mouse en-
grafted with human hematopoietic stem and progenitor cells
can support the replication of S. Typhi and can serve as a model
to study this human-specific pathogen. Humanizing the immune
system of the mouse effectively relieved the potent host-speci-
ficity barrier that blocks S. Typhi replication in this species andr Inc.
Figure 3. S. Typhi Stimulates a Human Innate and Acquired Immune Response in Humanized Mice
(A) Human cytokine and chemokine concentrations in the sera of control and humanized animals. Sera were collected from the uninfected or infected animals
1 week (1w) or 4 weeks (4w) after infection.
(B) Human immunoglobulin (IgG, M, and A) levels against S. Typhi in the sera of control and humanized animals that were left uninfected or infected for 4 weeks
with either wild-type (WT) or DphoP DphoQ mutant (DphoPQ) S. Typhi.
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ence of human cells rendersmice permissive forS. Typhi replica-
tion. Human cells may simply provide a permissive niche for
bacterial replication. Indeed, we have observed replicating
S. Typhi within human cells in the engrafted animals. However,
it is also possible that the human cells help S. Typhi to overcome
some (yet unknown) ‘‘bottleneck’’ that prevents the progression
of S. Typhi infection. Our results have shown that S. Typhi infec-
tion in humanized mice is very different from that of S. Typhimu-
rium in conventional mice. This is highlighted by the observation
that the Nramp1 protein, which plays a dominant role in confer-
ring resistance to S. Typhimurium, did not influence the suscep-
tibility of humanized mice to S. Typhi. Infection of humanized
mice did not lead to acute lethal infection (i.e., murine typhoid),
although it led to persistent infection, a very poorly understood
aspect of S. Typhi pathogenesis. It is not clear why humanized
animals did not develop symptoms of systemic infection despite
the presence of a large number of bacteria in various tissues.Cell HosHowever, it is likely that the inability of the human cytokines
to effectively act on mouse tissues (Libert et al., 1990; Manz,
2007; Schoenhaut et al., 1992) may prevent the development
of systemic pathology. Future improvements on this mouse
model may allow the modeling of systemic pathology and may
increase the consistency of the engrafted animals to support
infection and immune responses. The detailed study of S. Typhi
infection in the humanized mouse model described here may
lead to a better understanding of several aspects of human
S. Typhi pathogenesis. One of the most significant hurdles for
the development of S. Typhi vaccines has been the absence of
a convenient animal model that can be used to test virulence-
attenuated mutants and evaluate their vaccine potential. It is
known that immunization or even virulence studies in conven-
tional mice often do not translate well into humans. The model
described here may therefore greatly facilitate the development
and preclinical testing of typhoid fever therapeutic and preven-
tion strategies.t & Microbe 8, 369–376, October 21, 2010 ª2010 Elsevier Inc. 373
Figure 4. Replication of S. Typhi DphoP DphoQ or DpltB (Typhoid
Toxin-Defective) Mutant Strains in Humanized Mice
(A and B) Total cfu in the spleen (A) and liver (B) of control (Ctrl) and humanized
(Hu) animals 4weeks after intraperitoneal administration of 104 cfu of wild-type
S. Typhi (WT) or its isogenic mutant strains DphoP DphoQ or a DpltB (typhoid
toxin-defective). Data represent two pooled independent experiments. Each
dot represents the number of cfu per organ of a single mouse. The mean
±SEMof the cfu for each group of mice is shown. The p values of the difference
between the cfu obtained from humanized animals infected with wild-type and
the DphoP DphoQ mutant and the difference between the cfu obtained from
animals infected with wild-type and the DpltB mutant strains are also shown.
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Engraftment of Mice with Human Hematopoietic CD34+ Stem
and Progenitor Cells
Rag2/ gc/ mice were provided by Regeneron Pharmaceuticals (Tarry-
town, NY). These mice were derived from a V17 embryonic stem cell line
(BALB/c 3 129 heterozygote) targeted for the Rag2 and Il2rg genes. Human
fetal liver samples were obtained under approval from the Yale University
Human Investigation Committee from Albert Einstein Medical College, New
York. CD34+ cells were purified by density gradient centrifugation and immu-
nomagnetic selection using CD34microbeads (Miltenyi Biotec; BergischGlad-
bach, Germany). Newborn pups were irradiated and engrafted with human374 Cell Host & Microbe 8, 369–376, October 21, 2010 ª2010 ElsevieCD34+ cells (1–2 3 105 cells in PBS) as previously described (Traggiai et al.,
2004). Control mice were injected with PBS only. Engraftment with human
hematopoietic cells was determined 8–14 weeks posttransplantation by
retro-orbital bleeding and flow cytometry as described below. Mice used for
experiments had blood engraftment levels of R15% hCD45+ cells. Mice
were maintained under specific-pathogen-free conditions and received
prophylactic antibiotics (Sulfatrim) in the drinking water to prevent opportu-
nistic infections until 2 weeks prior to S. Typhi infection. All animal work was
approved by the Yale University Institutional Animal Care and Use Committee
(IACUC) and conducted in accordance with IACUC regulations.
Flow Cytometry
Cell suspensions were prepared from bone marrow, spleen, and blood of mice
10–14 weeks posttransplantation. Lysis of RBC was performed using ACK
lysis buffer (Lonza, Basel). Samples were then stained with fluorochrome-
labeled monoclonal antibodies (mAbs) against mouse and human cell surface
antigens. The following mAbs were used: (1) anti-human: CD3 (UCHT1),
CD11c (B-ly6), CD14 (MoP9), CD19 (HIB19), CD33 (WM53), CD45 (HI30 and
2D1), CD66 (B1.1); (2) anti-mouse: CD45 (30-F11). CD45 (30-F11) mAb was
from eBioscience (San Diego, CA). All other mAbs were from BD Biosciences
(San Jose, CA). Samples were analyzed on a FACSCalibur or LSR II flow
cytometer (BD Biosciences).
Bacterial Strains, Media, and Growth Conditions
The wild-type S. enterica serovar Typhi strain ISP2825 and its isogenic DpltB
mutant have been described previously (Gala´n and Curtiss, 1991; Spano` et al.,
2008). A mutant strain carrying an in-frame deletion in DphoP DphoQ in the
chromosome was constructed by standard recombinant DNA and allelic
exchange procedures as previously described (Kaniga et al., 1994). S. Typhi
strains were grown overnight at 37C in 2ml LB broth. Formouse experiments,
overnight cultures of bacteria were freshly inoculated at a dilution of 1:50 in LB
broth containing 0.3 M NaCl and grown at 37C to an OD600 of0.8. Indicated
numbers of bacteria were prepared in buffered saline with gelatin (BSG) (8.5 g
NaCl, 0.3 g KH2PO4, 0.6 g Na2HPO4, 0.1 g gelatin in 1000ml distilled water [pH
7.0]) for mouse experiments. All S. Typhi strains used in these studies were
verified to be Vi antigen positive.
Bacterial Infections and Colony-Forming Units Assay
All animal experiments were conducted according to protocols approved by
Yale University’s Institutional Animal Care and Use Committee. Groups of
control and humanized 13- to 16-week-old mice were infected intraperitone-
ally with either 104 or 105 wild-type S. Typhi or the isogenic DphoP DphoQ
or DpltB mutant strains in 100 ml of BSG. Infected animals were sacrificed
and organs were harvested at 5, 11, 21, and 28 days postinfection to perform
in vivo cfu assays. Spleens, livers, and gall bladders were aseptically removed
and mechanically homogenized in 3 ml (for spleens and gall bladders) or 5 ml
(for livers) sterile PBS containing 0.05% sodium deoxycholate. Bacterial loads
were determined by plating 10-fold serial dilutions of homogenates on LB agar
plates and incubated overnight at 37C. Colonies were counted and the
number of total cfu recovered was calculated.
Immunofluorescence of Spleen Sections
Control and humanized 12- to 14-week-old mice were infected intraperitone-
ally with 106 S. Typhi in 100 ml BSG. Five days after infection, spleens were
aseptically removed, fixed in 3.7% formaldehyde overnight, paraffin
embedded, and cut 5 mm thick. Tissue sections were pretreated at 95C for
20 min in 10 mM citrate buffer (pH 6.0) to retrieve the epitope and followed
by 30 min incubation at RT with the primary antibodies. Monoclonal mouse
anti-human CD45, leukocyte common antigen (LCA) clones 2B11 + PD7/26
(Dako; Glostrup, Denmark; 1:100 dilution) and monoclonal rat anti-mouse
CD45, LCA clone 30-F11 (BD PharMingen; San Jose, CA; 1:40 dilution) anti-
bodies were used to detect human andmouse CD45+ cells on spleen sections.
Polyclonal rabbit anti-S. Typhi lipopolysaccharide (Difco Laboratories [BD
Biosciences]; San Jose, CA; 1:1000 dilution) antibodywas used to detect intra-
cellular bacteria. The tissue sections were then incubated for 20min at RT with
secondary anti-mouse, anti-rat, or anti-rabbit antibodies conjugated with FITC
(Biocare Medical; Concord, CA) or DyLight549 (Biocare Medical). Slides werer Inc.
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H1200).
Peripheral Blood Leukocyte Preparation, Splenocyte Preparation,
Immunostaining, and FACS Analysis
Peripheral blood of uninfected and infected humanized mice was collected
into heparinized tubes. In order to remove RBCs, 100 ml heparinized blood
was incubated with 1 ml ACK lysis buffer (Lonza) for 5 min on ice, washed
with 2 ml PBS, and centrifuged to collect peripheral blood leukocytes
(PBLs). This RBC-lysis step was repeated once more, and PBLs were imme-
diately processed for an immunostaining as described below. Spleens of unin-
fected and infected humanizedmice were aseptically harvested, mechanically
homogenized, and filtered using a nylon mesh to obtain single-cell suspen-
sions. RBCs were lysed by incubating them with 1 ml ACK lysis buffer. After
washing, cells were immediately incubated for 30 min on ice with 100 ml of
an antibody cocktail containing anti-mouse CD45 (30-F11; eBioscience) and
anti-human CD45 (HI30 and 2D1; BD Biosciences), CD3 (UCHT1; BD Biosci-
ences), and CD19 (HIB19; BD Biosciences). The cells were then washed
with 2 ml FACS buffer (0.16% BSA/0.1% NaN3/PBS), resuspended in 100 ml
FACS fix buffer (1% FCS/1% Formaldehyde/PBS), kept at 4C overnight,
and used for FACS analyses. Total splenocyte numbers were determined by
cell counting using a hemocytometer.
Human Cytokine/Chemokine Measurement
Human cytokine/chemokine concentration in the sera of control and human-
ized animals were measured using a human cytokines/chemokines/growth
factors multiplex kit (Millipore; Billerica, MA) according to the manufacturer’s
protocol. The following human cytokines were assayed: Eotaxin, G-CSF,
GM-CSF, IFN-a2, IFN-g, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17,
IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1a,
MIP-1b, TNF-a, and TNF-b. Only human cytokines that showed a significant
elevation in serum after S. Typhi infection are shown in Figure 3. The other
cytokines were either not detected or detected in a small subset of infected
animals.
Measurement of Human S. Typhi-Specific Antibody Responses
Human S. Typhi-specific antibody levels in the sera of infected humanized
mice were examined using a direct ELISA. ELISA plates were coated with
a S. Typhi total cell lysate prepared as follows: S. Typhi was cultured in
50 ml LB broth, heat killed at 70C for 20 min, centrifuged, and resuspended
in 50 mM Tris buffer (pH 8.0) containing 1% Triton X-100 and a protease inhib-
itor cocktail (Roche, Basel). The bacterial cells were then sonicated, and
unbroken cells were removed by centrifugation. 96-well plates (Maxisorp,
Nunc; Rochester, NY) were coated with 30 mg bacterial cell lysates in 100 ml
plate-coating buffer (0.5 M carbonate-bicarbonate buffer [pH 9.6]) (per well)
and incubated overnight at 4C. Wells were washed with PBS containing
0.05% Tween 20 and blocked with PBS containing 1% BSA for 1 hr at 37C.
Two-fold serial dilution of the sera contained in 50 ml PBS/0.05% Tween 20/
0.5% BSA was added into each well and incubated for 2 hr at 37C. After
washing, bound antibodies were detected with HRP-conjugated anti-human
immunoglobulin (IgM, IgG, and IgA; SouthernBiotech; Birmingham, AL) at
a 1:4000 dilution in PBS/0.05% Tween 20/0.5% BSA. Wells were then incu-
bated with a HRP substrate, tetramethylbenzidine (TMB; Sigma, St. Louis),
for 10–30 min, and the reaction was stopped by addition of 100 ml of 1M
H3PO4. Relative serum antibody levels were determined by standard end-
point ELISA titration.
nramp1 Genotyping
Tail biopsies from sacrificed animals were incubated in 500 ml DNA digestion
buffer (50 mM Tris-HCl [pH 8.0], 100 mM EDTA [pH 8.0], 100 mM NaCl, 1%
SDS, and 0.5 mg/ml protease K) overnight at 53C with gentle shaking. The
following day, supernatants were taken after microcentrifugation at maximum
speed for 10min. One volume of isopropanol wasmixed with the supernatants
to precipitate DNA. DNA pellet was obtained by microcentrifugation, resus-
pended in 50 ml TE buffer, and used for nramp1 PCR amplification. A 514 bp
fragment of the nramp1 gene was amplified by PCR using primers 50-AAGTG
ACATCTCGCCATAGGTGCC-30 (forward) and 50-TTCTCTCACCATAGTTATCCell HosCAAGAAG-30 (reverse). The purified PCR product was then sequenced using
the primer 50-CCCCCATCTATGTTATCACCC-30.
Statistics
Statistical analysis was conducted with the two-tailed Mann-Whitney test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article online at doi:10.1016/j.chom.2010.09.003.
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